The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

Fewer than half of heart patients from 17 countries who could benefit from beneficial drugs are taking them, researchers ...

Local event will screen Denver residents for Lp(a), a dangerous type of cholesterol and heart risk most doctors are not routinely testing for, as well as certain other metabolism and kidney risks ...

Get free kidney and heart screenings at Falam Baptist Church of Indiana this week. No insurance required, appointments available Feb. 13-15.